These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. Morizono K; Xie Y; Helguera G; Daniels TR; Lane TF; Penichet ML; Chen IS J Gene Med; 2009 Aug; 11(8):655-63. PubMed ID: 19455593 [TBL] [Abstract][Full Text] [Related]
8. Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies. Purow B; Staveley-O'Carroll K J Surg Res; 2005 Jan; 123(1):49-54. PubMed ID: 15652950 [TBL] [Abstract][Full Text] [Related]
9. Development of adenovirus immobilization strategies for in situ gene therapy. Hu WW; Lang MW; Krebsbach PH J Gene Med; 2008 Oct; 10(10):1102-12. PubMed ID: 18618417 [TBL] [Abstract][Full Text] [Related]
11. Introduction of histidine residues into avidin subunit interfaces allows pH-dependent regulation of quaternary structure and biotin binding. Nordlund HR; Hytönen VP; Laitinen OH; Uotila ST; Niskanen EA; Savolainen J; Porkka E; Kulomaa MS FEBS Lett; 2003 Dec; 555(3):449-54. PubMed ID: 14675754 [TBL] [Abstract][Full Text] [Related]
12. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Campos SK; Barry MA Virology; 2006 Jun; 349(2):453-62. PubMed ID: 16504233 [TBL] [Abstract][Full Text] [Related]
13. Switchavidin: reversible biotin-avidin-biotin bridges with high affinity and specificity. Taskinen B; Zauner D; Lehtonen SI; Koskinen M; Thomson C; Kähkönen N; Kukkurainen S; Määttä JA; Ihalainen TO; Kulomaa MS; Gruber HJ; Hytönen VP Bioconjug Chem; 2014 Dec; 25(12):2233-43. PubMed ID: 25405260 [TBL] [Abstract][Full Text] [Related]
14. Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules. Lehtolainen P; Taskinen A; Laukkanen J; Airenne KJ; Heino S; Lappalainen M; Ojala K; Marjomäki V; Martin JF; Kulomaa MS; Ylä-Herttuala S J Biol Chem; 2002 Mar; 277(10):8545-50. PubMed ID: 11741995 [TBL] [Abstract][Full Text] [Related]
15. In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles. Maldiney T; Kaikkonen MU; Seguin J; le Masne de Chermont Q; Bessodes M; Airenne KJ; Ylä-Herttuala S; Scherman D; Richard C Bioconjug Chem; 2012 Mar; 23(3):472-8. PubMed ID: 22250884 [TBL] [Abstract][Full Text] [Related]
16. Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes. Soininen SK; Lehtolainen-Dalkilic P; Karppinen T; Puustinen T; Dragneva G; Kaikkonen MU; Jauhiainen M; Allart B; Selwood DL; Wirth T; Lesch HP; Määttä AM; Mönkkönen J; Ylä-Herttuala S; Ruponen M Eur J Pharm Sci; 2012 Dec; 47(5):848-56. PubMed ID: 22985874 [TBL] [Abstract][Full Text] [Related]
17. Conditional expression of Lodavin, an avidin-tagged LDL receptor, for biotin-mediated applications in vivo. Murugan S; Saarela U; Airenne K; Shan J; Skovorodkin I; Ylä-Herttuala S; Vainio SJ Genesis; 2012 Sep; 50(9):693-9. PubMed ID: 22467513 [TBL] [Abstract][Full Text] [Related]
18. Avidin-biotin technology in targeted therapy. Lesch HP; Kaikkonen MU; Pikkarainen JT; Ylä-Herttuala S Expert Opin Drug Deliv; 2010 May; 7(5):551-64. PubMed ID: 20233034 [TBL] [Abstract][Full Text] [Related]
19. Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells. Ojala K; Mottershead DG; Suokko A; Oker-Blom C Biochem Biophys Res Commun; 2001 Jun; 284(3):777-84. PubMed ID: 11396970 [TBL] [Abstract][Full Text] [Related]
20. Virus immobilization on biomaterial scaffolds through biotin-avidin interaction for improving bone regeneration. Hu WW; Wang Z; Krebsbach PH J Tissue Eng Regen Med; 2016 Feb; 10(2):E63-72. PubMed ID: 23798490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]